On October 26, Winbond Health issued an announcement stating that its wholly-owned subsidiary Winbond Pharmaceuticals had recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration for injection of methylprednisolone sodium succinate.
Methylprednisolone sodium succinate for injection is a kind of freeze-dried powder of glucocorticoid drugs.
It has strong anti-inflammatory, anti-allergic, anti-shock, and immunosuppressive effects.
It is clinically used in acute and critically ill patients.
Period, and maintenance treatment after first aid
Mainly used for anti-inflammatory therapy, immunosuppressive therapy, blood disease, tumor, shock therapy, endocrine disorders
It is especially suitable for disease states that require rapid treatment with strong action and quick onset
According to the enlarged version of the hospital data (including urban public hospitals, county-level public hospitals, urban community hospitals, and township health centers) on Minai.
com, the sales of methylprednisolone sodium succinate for injection in 2019 and 2020 are about approximately 2.
4 billion yuan and 1.
9 billion yuan, including specifications of 20mg, 40mg, 125mg, 250mg, 500mg, 1.
0g, of which the market-leading specification is 40mg.
The sales of this specification in 2019 and 2020 are about It was 1.
73 billion yuan and 1.
341 billion yuan
Winbond Pharmaceuticals currently has 40mg and 500mg methylprednisolone sodium succinate specifications for injection.
The 40mg specification that passed the generic drug consistency evaluation this time was passed.
The 500mg specification passed the consistency evaluation in June 2021
Winbond Pharmaceuticals, as the third company to pass the consistency evaluation of methylprednisolone sodium succinate (40mg) for injection, will be eligible to participate in the national centralized procurement